NO960303L - Antisens-oligonukleotidhemming av ekspresjon av vaskulær endotelial vekstfaktor - Google Patents
Antisens-oligonukleotidhemming av ekspresjon av vaskulær endotelial vekstfaktorInfo
- Publication number
- NO960303L NO960303L NO960303A NO960303A NO960303L NO 960303 L NO960303 L NO 960303L NO 960303 A NO960303 A NO 960303A NO 960303 A NO960303 A NO 960303A NO 960303 L NO960303 L NO 960303L
- Authority
- NO
- Norway
- Prior art keywords
- vegf
- growth factor
- endothelial growth
- vascular endothelial
- oligonucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/316—Phosphonothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Vaskulær endotelial vekstfaktor (VEGF), også kjent som vaskulær permeabilitetsfaktor (VPF), har blitt vist å spille en viktig rolle l abnormal anglogenese forbundet med forskjellige patologiske tilstander. Det blir her beskrevet forbindelser, sammensetninger og fremgangs- måter for hemming av silke abnormale anglogenser. Spesielt blir det beskrevet flere antlsens-ollgonukleo- tlder fra 19 til 21 baser lange som binder til VEGF RNA, og som hemmer produksjon av ekspresjonsproduktet. Disse antlsens-oligonukletidene er nyttige i behand- lingen av patologiske tilstander i hvilke VEGF-ekspre- sjon spiller en rolle. Oligonukleotidene er komplementere til deler av VEGF mRNA og VEGF genet, deriblant til start- og stoppsekvenser. Oliognukleotidene er stabilisert ved at forsfodiesterbindingene er modifisert (fosforthioatintemukleotidbindinger).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/098,942 US6410322B1 (en) | 1993-07-27 | 1993-07-27 | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
PCT/US1994/008537 WO1995004142A2 (en) | 1993-07-27 | 1994-07-26 | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
Publications (2)
Publication Number | Publication Date |
---|---|
NO960303D0 NO960303D0 (no) | 1996-01-25 |
NO960303L true NO960303L (no) | 1996-03-13 |
Family
ID=22271667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO960303A NO960303L (no) | 1993-07-27 | 1996-01-25 | Antisens-oligonukleotidhemming av ekspresjon av vaskulær endotelial vekstfaktor |
Country Status (9)
Country | Link |
---|---|
US (1) | US6410322B1 (no) |
EP (1) | EP0711343A1 (no) |
JP (1) | JPH09503651A (no) |
CN (1) | CN1131437A (no) |
AU (1) | AU7516894A (no) |
CA (1) | CA2167680A1 (no) |
FI (1) | FI960374A (no) |
NO (1) | NO960303L (no) |
WO (1) | WO1995004142A2 (no) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7238673B2 (en) * | 1989-03-31 | 2007-07-03 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5641756A (en) * | 1993-07-27 | 1997-06-24 | Hybridon, Inc. | Modified VEGF oligonucleotides |
US5639872A (en) * | 1993-07-27 | 1997-06-17 | Hybridon, Inc. | Human VEGF-specific oligonucleotides |
US5731294A (en) * | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
US6150092A (en) * | 1994-06-27 | 2000-11-21 | Taogosei Company, Ltd. | Antisense nucleic acid compound targeted to VEGF |
MY134778A (en) * | 1995-10-23 | 2007-12-31 | Hyal Pharmaceutical Australia Ltd | Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization |
AU721060B2 (en) * | 1995-10-23 | 2000-06-22 | Meditech Research Limited | Hyaluronic acid as DNA carrier for gene therapy and VEGF antisense DNA to treat abnormal retinal vascularization |
US6346398B1 (en) | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
AU769175B2 (en) * | 1995-10-26 | 2004-01-15 | Chiron Corporation | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
US7034009B2 (en) | 1995-10-26 | 2006-04-25 | Sirna Therapeutics, Inc. | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
JP2000501941A (ja) * | 1995-12-08 | 2000-02-22 | ハイブリドン・インコーポレイテッド | 修飾vegfアンチセンスオリゴヌクレオチド |
WO1997020925A1 (en) * | 1995-12-08 | 1997-06-12 | Hybridon, Inc. | Modified vegf antisense oligonucleotides for treatment of skin disorders |
EP0910634A2 (en) * | 1996-04-17 | 1999-04-28 | Hoechst Marion Roussel Deutschland GmbH | ANTISENSE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEgF/VPF) EXPRESSION |
US6790443B2 (en) * | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
US6486133B1 (en) | 1997-03-07 | 2002-11-26 | The Wistar Institute Of Anatomy And Biology | Methods for inducing localized vascular development and enhancing the repair of a wound in the mammamian dermis |
NZ500427A (en) | 1997-04-21 | 2002-12-20 | Univ Florida | The use of ribozyme treatment for retinal diseases |
CN1063755C (zh) * | 1997-07-24 | 2001-03-28 | 中国科学院上海生物化学研究所 | 血管内皮细胞生长因子反义寡聚脱氧核苷酸 |
JPH1142091A (ja) * | 1997-07-25 | 1999-02-16 | Toagosei Co Ltd | アンチセンス核酸化合物 |
JP2001513559A (ja) | 1997-08-25 | 2001-09-04 | ブレム,ハロルド | 新脈管形成インヒビターを用いる癒着および過剰な瘢痕形成の予防 |
CN1069322C (zh) * | 1997-12-12 | 2001-08-08 | 中国人民解放军军事医学科学院放射医学研究所 | 反义寡核苷酸及用途 |
CN1057301C (zh) * | 1997-12-30 | 2000-10-11 | 杭州赛狮生物技术开发有限公司北京分公司 | 抑制人体肿瘤细胞生长的反义寡核苷酸 |
CN1056380C (zh) * | 1998-02-27 | 2000-09-13 | 中科院成都地奥制药公司 | 抑制人体恶性肿瘤生长的反义寡核苷酸 |
DE19813774A1 (de) * | 1998-03-27 | 1999-09-30 | Max Planck Gesellschaft | Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF) |
EP0979869A1 (en) * | 1998-08-07 | 2000-02-16 | Hoechst Marion Roussel Deutschland GmbH | Short oligonucleotides for the inhibition of VEGF expression |
DK1131073T3 (da) * | 1998-11-23 | 2004-02-02 | Novartis Ag | Anvendelse af staurosporinderivater til behandling af okulære neovaskulære sygdomme |
CA2368194A1 (en) | 1999-04-30 | 2000-11-09 | University Of Florida | Adeno-associated virus-delivered ribozyme compositions and methods of use |
EP1252308A2 (en) * | 2000-01-19 | 2002-10-30 | Parkash S. Gill | Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides |
US20070026394A1 (en) | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
EP1311277A4 (en) * | 2000-07-18 | 2004-08-25 | Joslin Diabetes Center Inc | FIBROSIS MODULATION METHOD |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
WO2003006478A1 (en) * | 2001-07-10 | 2003-01-23 | Oligos Etc. Inc. | Oligonucleotide-containing pharmacological compositions and their use |
DE60235761D1 (de) * | 2001-08-01 | 2010-05-06 | Univ Bristol Clifton | Isoform des vegfs |
WO2003018752A2 (en) | 2001-08-23 | 2003-03-06 | The Wistar Institute Of Anatomy And Biology | An organotypic intestinal culture and methods of use thereof |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
AU2003207708A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20050222061A1 (en) | 2002-04-18 | 2005-10-06 | Schulte Ralf W | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
US7435419B2 (en) * | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
BRPI0312818B8 (pt) * | 2002-07-19 | 2021-05-25 | Beth Israel Deaconess Medical Ct Inc | uso de uma medida do nível do polipeptídeo sflt-1 em uma amostra de uma paciente e uso de uma medida dos níveis de pelo menos dois dos peptídeos sflt1, vegf livre ou polipeptídio pigf livre em uma amostra de um paciente usando um métrico |
US7335362B2 (en) | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
PT2284266E (pt) * | 2002-11-14 | 2013-12-17 | Thermo Fisher Scient Biosciences Inc | Siarn contra tp53 |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
WO2005000223A2 (en) * | 2003-06-04 | 2005-01-06 | Children's Medical Center Corporation | Method of treating retinopathies and disorders associated with blood vessel loss |
KR101471732B1 (ko) * | 2003-08-27 | 2014-12-16 | 옵쏘테크 코포레이션 | 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법 |
CA2554212A1 (en) | 2004-02-10 | 2005-08-25 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sina) |
EP1773349A4 (en) * | 2004-05-04 | 2009-07-29 | Childrens Medical Center | METHODS AND COMPOSITIONS FOR TREATING PREECLAMPSIA |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US7740849B2 (en) * | 2004-09-24 | 2010-06-22 | Beth Israel Deaconess Medical Center | Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders |
JP5270161B2 (ja) * | 2004-09-24 | 2013-08-21 | ベス イスラエル デアコネス メディカル センター | 妊娠合併症を診断および処置する方法 |
US7955805B2 (en) * | 2004-12-15 | 2011-06-07 | Beth Israel Deaconess Medical Center | Nucleic acids and polypeptides useful for diagnosing complications of pregnancy |
WO2007013704A1 (en) * | 2005-07-27 | 2007-02-01 | Juseong College Industry Academy Cooperation Group | Recombinant adeno-associated virus comprising antisense cdnas of vegf-a, vegf-b and vegf-c and gene therapeutic agent specific to large intestine cancer, bladder cancer and/or lung cancer comprising the same |
WO2007058323A1 (ja) * | 2005-11-17 | 2007-05-24 | Napa Jenomics Co., Ltd. | 核酸ホモポリマー結合機能性核酸医薬品の製造法 |
CN100371444C (zh) * | 2005-12-12 | 2008-02-27 | 清华大学深圳研究生院 | 一种抑制VEGF表达的siRNA及其应用 |
US20090286271A1 (en) * | 2006-05-31 | 2009-11-19 | Karumanchi Ananth S | Methods of Diagnosing and Treating Complications of Pregnancy |
CN101970670B (zh) * | 2008-01-14 | 2013-08-21 | 健泰科生物技术公司 | 使用egfl8拮抗剂抑制血管发生的方法 |
EP2361306A1 (en) | 2008-12-04 | 2011-08-31 | OPKO Ophthalmics, LLC | Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms |
EP2370581B1 (en) * | 2008-12-04 | 2016-08-03 | CuRNA, Inc. | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
CN103223177B (zh) * | 2009-05-06 | 2016-08-10 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
EP2598639A4 (en) | 2010-07-28 | 2014-08-13 | Alcon Res Ltd | SIRNA TARGETED VEGFA AND IN VIVO TREATMENT PROCESS WITH THIS |
WO2012027206A1 (en) | 2010-08-24 | 2012-03-01 | Merck Sharp & Dohme Corp. | SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
JP2016531901A (ja) | 2013-07-12 | 2016-10-13 | オプソテック コーポレイションOphthotech Corporation | 眼科症状を処置するまたは予防するための方法 |
US10160973B2 (en) | 2015-03-30 | 2018-12-25 | Nissan Chemical Industries, Ltd. | Nucleic acid aptamers binding to vascular endothelial growth factor receptors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456550A (en) | 1982-11-22 | 1984-06-26 | President And Fellows Of Harvard College | Vascular permeability factor |
US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5149797A (en) * | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
-
1993
- 1993-07-27 US US08/098,942 patent/US6410322B1/en not_active Expired - Fee Related
-
1994
- 1994-07-26 CN CN94193482A patent/CN1131437A/zh active Pending
- 1994-07-26 JP JP7505976A patent/JPH09503651A/ja active Pending
- 1994-07-26 AU AU75168/94A patent/AU7516894A/en not_active Abandoned
- 1994-07-26 CA CA002167680A patent/CA2167680A1/en not_active Abandoned
- 1994-07-26 EP EP94925136A patent/EP0711343A1/en not_active Withdrawn
- 1994-07-26 WO PCT/US1994/008537 patent/WO1995004142A2/en not_active Application Discontinuation
-
1996
- 1996-01-25 NO NO960303A patent/NO960303L/no unknown
- 1996-01-26 FI FI960374A patent/FI960374A/fi not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU7516894A (en) | 1995-02-28 |
CA2167680A1 (en) | 1995-02-09 |
WO1995004142A2 (en) | 1995-02-09 |
FI960374A (fi) | 1996-03-25 |
FI960374A0 (fi) | 1996-01-26 |
US6410322B1 (en) | 2002-06-25 |
CN1131437A (zh) | 1996-09-18 |
EP0711343A1 (en) | 1996-05-15 |
NO960303D0 (no) | 1996-01-25 |
JPH09503651A (ja) | 1997-04-15 |
WO1995004142A3 (en) | 1995-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO960303L (no) | Antisens-oligonukleotidhemming av ekspresjon av vaskulær endotelial vekstfaktor | |
WO2004065601A3 (en) | Lipophilic derivatives of double-stranded ribonucleic acid | |
BG102072A (en) | Rotamase enzymic activity inhibitors | |
GB0230162D0 (en) | Compounds useful in inhibiting angiogenesis | |
ZA200304500B (en) | Method for inhibiting the expression of a target gene and medicament for treating a tumor disease. | |
WO2002046171A3 (en) | Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto | |
WO2002055693A3 (de) | Verfahren zur hemmung der expression eines zielgens | |
ZA200508830B (en) | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors | |
CA2359180A1 (en) | Method and medicament for inhibiting the expression of a given gene | |
MY119800A (en) | Pyridine derivatives | |
WO2005099770A3 (en) | Pancreatic islet microrna and methods for inhibiting same | |
WO1997039120A3 (en) | Antisense inhibitors of vascular endothelial growth factor (vefg/vpf) expression | |
IL140419A0 (en) | Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same | |
WO2002004466A3 (en) | Catalyst for asymmetric (transfer) hydrogenation | |
AU7246801A (en) | Novel rare earth metal cryptates which are not very sensitive to the fluorescence quenching | |
WO2001052904A3 (en) | Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides | |
PL1751093T3 (pl) | Podstawione pochodne kwasu cykloheksylooctowego | |
WO2001032832A3 (en) | Antisense inhibition of nucleolin expression | |
WO2003006670A3 (en) | 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors | |
DK0998566T3 (da) | Fröplanter kendetegnet ved forsinket fröspredning | |
WO2003101386A3 (en) | Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis | |
CA2294305A1 (en) | Antisense oligonucleotide sequences as inhibitors of microorganisms | |
WO2002014313A3 (de) | Neue beta-amyloid inhibitoren, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
CA2341638A1 (en) | Use of a midkine inhibitor | |
Emre et al. | Histone H2B ubiquitylation and deubiquitylation in genomic regulation |